Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection
Kuo‐Yen Huang, M. L. Lin, Ting‐Chun Kuo, et al.
EMBO Molecular Medicine (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Human organoid models to study SARS-CoV-2 infection
Yuling Han, Liuliu Yang, Lauretta A. Lacko, et al.
Nature Methods (2022) Vol. 19, Iss. 4, pp. 418-428
Open Access | Times Cited: 100
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Shiho Tanaka, Gard Nelson, C. Anders Olson, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 65
Is Covid-19 Severity Associated With ACE2 Degradation?
Ugo Bastolla, Patrick Chambers, David Abia, et al.
Frontiers in Drug Discovery (2022) Vol. 1
Open Access | Times Cited: 39
Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models
Yisheng Huang, Zhijie Huang, Zhengming Tang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 56
Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm
Zhen Wang, Lei Xiang, Feng Lin, et al.
Matter (2021) Vol. 5, Iss. 1, pp. 336-362
Open Access | Times Cited: 54
Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2
Chih‐Jung Kuo, Tai‐Ling Chao, Han‐Chieh Kao, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 4
Open Access | Times Cited: 41
Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses
Sui‐Yuan Chang, Kuo‐Yen Huang, Tai‐Ling Chao, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 36
BCEPS: A Web Server to Predict Linear B Cell Epitopes with Enhanced Immunogenicity and Cross-Reactivity
Alvaro Ras-Carmona, Hector F. Pelaez-Prestel, Esther M. Lafuente, et al.
Cells (2021) Vol. 10, Iss. 10, pp. 2744-2744
Open Access | Times Cited: 30
Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2
Yen‐Chung Lai, Yuwei Cheng, Chiao-Hsuan Chao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides
George N. Llewellyn, Hsu-Yu Chen, Geoffrey L. Rogers, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access | Times Cited: 12
Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks
Miao Cao, Xiaojie Su, Shibo Jiang
Stem Cell Reports (2021) Vol. 16, Iss. 3, pp. 398-411
Open Access | Times Cited: 24
ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern
Tsung-I Tsai, Jahan S. Khalili, Mark Gilchrist, et al.
Antiviral Research (2022) Vol. 199, pp. 105271-105271
Open Access | Times Cited: 18
Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations
Katharina Köchl, Tobias Schopper, Vedat Durmaz, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Effectiveness and Possible Side effects of the Covishield Vaccine in Preventing Covid-19
Pratibha Tiwari, Pratibha Tiwari, Pragna Patel
Asian Journal of Pharmaceutical Research (2025), pp. 176-182
Closed Access
Lung Organoids as Model to Study SARS-CoV-2 Infection
Li Peng, Li Gao, Xinya Wu, et al.
Cells (2022) Vol. 11, Iss. 17, pp. 2758-2758
Open Access | Times Cited: 15
Engineering a “muco‐trapping” ACE2‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID‐19
Karthik Tiruthani, Carlos Cruz‐Teran, Jasper Fuk‐Woo Chan, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 4
Open Access | Times Cited: 3
Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19
Jia‐You Fang, Kuo‐Yen Huang, Tong‐Hong Wang, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
In planta deglycosylation improves the SARS-CoV-2 neutralization activity of recombinant ACE2-Fc
Shiva Izadi, Ulrike Vavra, Stanislav Melnik, et al.
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 8
Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants
Cheng‐Pu Sun, Chi-Wen Chiu, Ping‐Yi Wu, et al.
Molecular Therapy (2023) Vol. 31, Iss. 11, pp. 3322-3336
Open Access | Times Cited: 8
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein
Hristo L. Svilenov, Julia Sacherl, A. Reiter, et al.
Antiviral Research (2021) Vol. 196, pp. 105197-105197
Open Access | Times Cited: 18
SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
Abigael Chaouat, Hagit Achdout, Inbal Kol, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 12, pp. e1010175-e1010175
Open Access | Times Cited: 18
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review
Lihua Qu, Chao Chen, Tong Yin, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11483-11483
Open Access | Times Cited: 17
Development trends of human organoid‐based COVID‐19 research based on bibliometric analysis
Minghui Li, Yuhong Yuan, Ting Zou, et al.
Cell Proliferation (2023) Vol. 56, Iss. 12
Open Access | Times Cited: 7
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Bruce D. Wines, Liriye Kurtovic, Halina M. Trist, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top